LC-FAOD program to move forward into the next stage of clinical development Enrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022 Alignment with European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA); single pivotal trial for registration of REN001… Continue reading Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
